Open an account

LadRx

LADX · OTC

$0.00+$0.0001 (−100.00%)TodayMarket closed ·
No price history for this range.

About LADX

LadRx Corp. is a biopharmaceutical research and development company. The company is headquartered in Los Angeles, California and currently employs 2 full-time employees. The firm focuses on the discovery, research and clinical development of anti-cancer drug candidates that employ technologies that target chemotherapeutic drugs to solid tumors and reduce off-target toxicities. The Company’s linker activated drug release (LADR) technology platform consists of an organic backbone that is attached to a chemo toxic agent. The LADR backbone is to first target and deliver the chemo toxic agent to the tumor environment, and then to release the chemo toxic agent within the tumor. The LADR Technology offers the opportunity for multiple pipeline drugs. The LADR development efforts are focused on two classes of ultra-high potency albumin-binding drugs. These LADR-based drugs, LADRs 7, 8, 9, and 10, combine the proprietary LADR backbone with derivatives of the auristatin and maytansinoid drug classes.

Employees
2
Headquarters
Los Angeles, California
Listed
Nov 10, 1986
Sector
Health Care
Industry
Biotechnology
Website
ladrxcorp.com

LADX key statistics

Market cap
99
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.24K
Volume
1
Open price
$0.00
High today
$0.0001
Low today
$0.00
52 Week high
$0.948
52 Week low
$0.00

LadRx (LADX) at a glance

LadRx (LADX) last traded at $0.00, with a market cap of 99 and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.00 and $0.0001. The current price is — above the day's low and 100.0% below its high.

Volume so far is 1 shares, below the average of 1.24K shares a day.

Over the past year LadRx has ranged from $0.00 to $0.948, and now sits 0% of the way up that range.

LadRx met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q1 FY19 it reported -$5.00 per share against an estimate of -$6.12.

LADX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 25.5% on average.

  1. Q2 FY16: reported -$162.00 per share against an estimate of -$116.28
  2. Q3 FY16: reported -$78.00 per share against an estimate of -$79.56
  3. Q4 FY16: reported -$36.00 per share against an estimate of -$67.32
  4. Q1 FY18: reported -$15.00 per share against an estimate of -$24.48
  5. Q2 FY18: reported -$10.00 per share against an estimate of -$18.36
  6. Q3 FY18: reported -$10.00 per share against an estimate of -$9.18
  7. Q4 FY18: reported -$7.00 per share against an estimate of -$7.14
  8. Q1 FY19: reported -$5.00 per share against an estimate of -$6.12

LADX news

  • Vandana Singh

    Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019

  • Press releaseBusiness Wire

    LadRx Planning NDA Submission under 505(b)(2) for Aldoxorubicin and Other Updates

Similar companies

Companies in the same industry as LadRx

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.